FDA approves BeiGene esophageal cancer drug
临床3期临床结果上市批准引进/卖出
The FDA has granted approval to BeiGene's Tevimbra (tislelizumab-jsgr), for treating adults with advanced or metastatic esophageal squamous cell carcinoma (ESCC) following prior systemic chemotherapy.
The nod marks the first U.S. indication for Tevimbra, expected to be available in the latter half of 2024. Tevimbra’s approval was supported by the results of the global phase 3 RATIONALE 302 trial, which demonstrated a significant survival advantage over traditional chemotherapy. Patients treated with Tevimbra experienced a median overall survival of 8.6 months, compared to 6.3 months for those on chemotherapy.
The drug has already received approval in Europe for the same condition and is under review for additional indications, including first-line ESCC treatment and as a therapy for non-small cell lung cancer. BeiGene is also conducting numerous trials to explore Tevimbra broader potential across various cancer types, with over 900,000 patients worldwide already treated.
Initially, BeiGene and Novartis collaborated on developing Tevimbra under a 2021 agreement that allowed Novartis to lead regulatory efforts and commercialize the drug worldwide post-approval. They've now amended this arrangement, granting BeiGene exclusive global rights to develop, manufacture and sell Tevimbra.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。